Oncolytics Biotech Inc T.ONC

SoftBank has acquired a $5 billion stake in Roche

[Noteable]

" According to the Bloomberg report, SoftBank was drawn to Roche largely because of its Genentech subsidiary. SoftBank allegedly believes the South San Francisco-based company is undervalued. Specifically, the investment bank is high on Aviv Regev, a computational and systems biologist who was recently hired by Genentech to lead its research unit. Regev pioneered methods for deciphering sequences of RNA in single cells. Additionally, she has created machine-learning algorithms for distilling biological knowledge from the resulting information. Those efforts resulted in the first demonstrations of the discovery of new insights into a range of molecular circuits, systems, and fields, including immunology, neurobiology, development, inflammatory disease, cancer, and evolution.

Sequencing has become a significant focus for Roche and Genentech. Over the past few years, Roche has made significant investments to bolster its precision medicine offerings that rely on sequencing. In 2018, Roche acquired Flatiron Health and its health oncology cloud platform." 

https://www.biospace.com/article/softbank-acquires-5-billion-stake-in-roche/?s=61